MuCopilot: Optimizing home-based monitoring for cystic fibrosis through digital biomarkers

At the 2025 Cystic Fibrosis Scientific Days (JSM), we presented the development work for MuCopilot®, our Software as a Medical Device (SaMD) dedicated to disease monitoring.

The study demonstrates the technical feasibility of measuring three key biomarkers using only smartphone sensors: respiratory function (phonation time), nighttime coughing, and endurance.

Through three usability studies involving 23 patients, a co-design approach led to 36 concrete improvements, ensuring a solution perfectly adapted to “real-life” conditions. These results set the stage for our upcoming clinical study of 70 patients, aimed at correlating these home-based measurements with clinical standards to achieve Class IIa Medical Device certification.